2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
---|---|---|---|---|---|
营业收入(元) | |||||
临床前研究服务(元) | 41,795,073.84 | 78,290,291.27 | 28,591,142.64 | 73,725,293.20 | 30,173,123.29 |
临床前自主研发(元) | - | 253,788.67 | - | 11,429,811.34 | 4,229,811.34 |
临床研究服务(元) | 271,384,282.64 | 414,510,164.45 | 173,847,970.66 | 277,119,134.36 | 114,848,813.14 |
技术成果转化服务(元) | - | - | - | 8,018,867.92 | - |
其他咨询服务(元) | 17,824,877.42 | 48,538,636.28 | 23,137,684.12 | 40,766,827.64 | 20,017,967.82 |
营业成本(元) | |||||
临床前研究服务(元) | 30,163,555.50 | 62,766,684.88 | 18,868,812.80 | 52,181,601.92 | 18,841,393.70 |
临床前自主研发(元) | - | - | - | 1,721,076.30 | 200,561.65 |
临床研究服务(元) | 186,615,965.06 | 279,045,573.36 | 116,474,162.93 | 185,768,572.77 | 77,668,608.82 |
技术成果转化服务(元) | - | - | - | 4,208,113.13 | - |
其他咨询服务(元) | 9,051,146.78 | 23,096,434.67 | 9,764,424.70 | 14,419,818.08 | 6,656,643.37 |
毛利(元) | |||||
临床前研究服务(元) | 11,631,518.34 | 15,523,606.39 | 9,722,329.84 | 21,543,691.28 | 11,331,729.59 |
临床前自主研发(元) | - | - | - | 9,708,735.04 | 4,029,249.69 |
临床研究服务(元) | 84,768,317.58 | 135,464,591.09 | 57,373,807.73 | 91,350,561.59 | 37,180,204.32 |
技术成果转化服务(元) | - | - | - | 3,810,754.79 | - |
其他咨询服务(元) | 8,773,730.64 | 25,442,201.61 | 13,373,259.42 | 26,347,009.56 | 13,361,324.45 |
毛利率(%) | |||||
临床前研究服务(%) | 27.83 | 19.83 | 34.00 | 29.22 | 37.56 |
临床前自主研发(%) | - | - | - | 84.94 | 95.26 |
临床研究服务(%) | 31.24 | 32.68 | 33.00 | 32.96 | 32.37 |
技术成果转化服务(%) | - | - | - | 47.52 | - |
其他咨询服务(%) | 49.22 | 52.42 | 57.80 | 64.63 | 66.75 |
收入构成(%) | |||||
临床前研究服务(%) | 12.63 | 14.46 | 12.67 | 17.94 | 17.83 |
临床前自主研发(%) | - | 0.05 | - | 2.78 | 2.50 |
临床研究服务(%) | 81.99 | 76.54 | 77.07 | 67.42 | 67.85 |
技术成果转化服务(%) | - | 0.00 | - | 1.95 | - |
其他咨询服务(%) | 5.39 | 8.96 | 10.26 | 9.92 | 11.83 |
毛利构成(%) | |||||
临床前研究服务(%) | 11.06 | 8.80 | 12.08 | 14.10 | 17.19 |
临床前自主研发(%) | - | 0.00 | - | 6.36 | 6.11 |
临床研究服务(%) | 80.60 | 76.78 | 71.30 | 59.80 | 56.42 |
技术成果转化服务(%) | - | 0.00 | - | 2.49 | - |
其他咨询服务(%) | 8.34 | 14.42 | 16.62 | 17.25 | 20.27 |